SCHEMBL2578664

SCHEMBL2578664

CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC/C=C\C/C=C\C/C=C\CC

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 3/20 0.79
PRKCE Q02156 2/20 0.79
PRKCQ Q04759 2/20 0.79
PRKCD Q05655 2/20 0.79
ALDH1A1 P00352 2/20 0.64
CYP3A4 P08684 1/20 0.64
ALOX15 P16050 1/20 0.64
TSHR P16473 1/20 0.64
HSD17B10 Q99714 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
S1PR1 P21453 1/20 0.64
FAAH O00519 3/20 0.64
MAPT P10636 1/20 0.64
HPGD P15428 1/20 0.64
CNR1 P21554 1/20 0.64
CNR2 P34972 1/20 0.64
SELP P16109 1/20 0.61
NR1I2 O75469 1/20 0.56
PGR P06401 1/20 0.56
ADORA3 P0DMS8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13481433 1.00 PRKCA (0.79) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL29934740 1.00 PRKCA (0.79) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL29934675 1.00 PRKCA (0.79) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL29934864 1.00 PRKCA (0.79) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL29935123 1.00 PRKCA (0.79) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL2581704 1.00 PRKCA (0.79) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL29934264 1.00 PRKCA (0.79) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL29934263 1.00 PRKCA (0.79) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL29934738 1.00 PRKCA (0.79) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL29651586 0.99 PRKCA (0.77) PRKCAPRKCEPRKCQPRKCDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547455-B2 Cancer and inflammatory disorder treatment ACADEMIA SINICA (TW) 2009-06-16 US claimed
US-20080152737-A1 CANCER AND INFLAMMATORY DISORDER TREATMENT ACADEMIA SINICA (TW) 2008-06-26 US claimed
US-20260000768-A1 APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT, AND RELATED PRODUCTS BEIJING BAISHIHEKANG PHARMACEUTICAL TECH BSJPHARMA CO LTD (CN) 2026-01-01 US disclosed
US-20250345290-A1 APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT AND RELATED PRODUCTS THEREOF BEIJING BAISHIHEKANG PHARMACEUTICAL TECH BSJPHARMA CO LTD (CN) 2025-11-13 US disclosed
US-12280114-B2 Extraction of plant source “medicinal soup” and manual preparation of “herbal medicine” and related products INSTITUTE OF BASIC MEDICAL SCIENCES (CN) 2025-04-22 US disclosed
US-20250041423-A1 EXTRACTION OF PLANT SOURCE \"MEDICINAL SOUP\" AND MANUAL PREPARATION OF \"HERBAL MEDICINE\" AND RELATED PRODUCTS BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) 2025-02-06 US disclosed
WO-2024211809-A1 METHODS AND COMPOSITIONS FOR INCREASING PROTEIN AND/OR OIL CONTENT AND/OR OIL PROFILE IN A PLANT SYNGENTA CROP PROTECTION AG (CH) 2024-10-10 WO disclosed
CN-115308340-B Method for detecting cold-resistant marker in winter rape overwintering period and application 甘肃农业大学 2023-11-14 CN disclosed
US-20220291237-A1 Gene Expression Inflammatory Age and Its Uses Edifice Health, Inc. (US) 2022-09-15 US disclosed
US-8048455-B2 Treatment of cancer and inflammatory disorder ACADEMIA SINICA (TW) 2011-11-01 US disclosed
US-20110064794-A1 Drug Delivery System, its Preparation Process and Use SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-03-17 US disclosed
US-20100317603-A1 Treatment of Cancer and Inflammatory Disorder ACADEMIA SINICA (TW) 2010-12-16 US disclosed
US-7547455-B2 Cancer and inflammatory disorder treatment ACADEMIA SINICA (TW) 2009-06-16 US disclosed
US-20080152737-A1 CANCER AND INFLAMMATORY DISORDER TREATMENT ACADEMIA SINICA (TW) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260000768-A1 APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT, AND RELATED PRODUCTS FABP2, NSUN2, TRDMT1 PRKCA 1593/4885PRKCE 3068/4885PRKCQ 2159/4885
US-20250345290-A1 APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT AND RELATED PRODUCTS THEREOF TRDMT1, HNRNPAB, HNRNPA1 PRKCA 2378/4885PRKCE 3922/4885PRKCQ 3379/4885
US-12280114-B2 Extraction of plant source “medicinal soup” and manual preparation of “herbal medicine” and related products CHMP4B, FIP1L1, LIPC PRKCA 55/4885PRKCE 194/4885PRKCQ 343/4885
US-20250041423-A1 EXTRACTION OF PLANT SOURCE \"MEDICINAL SOUP\" AND MANUAL PREPARATION OF \"HERBAL MEDICINE\" AND RELATED PRODUCTS CHMP4B, EXOSC5, FIP1L1 PRKCA 164/4885PRKCE 846/4885PRKCQ 902/4885
US-20100317603-A1 Treatment of Cancer and Inflammatory Disorder TNF, LITAF, NFKBIA PRKCA 2002/4885PRKCE 1988/4885PRKCQ 2327/4885
US-20080152737-A1 CANCER AND INFLAMMATORY DISORDER TREATMENT TNF, NFKBIA, RELA PRKCA 2164/4885PRKCE 2183/4885PRKCQ 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.